An Open-label, Long-term Extension Study to Evaluate the Safety, Tolerability and Efficacy of 12 Months of LCZ696 Treatment in Patients With Essential Hypertension [EXTENSION OF 700059183]

Trial Profile

An Open-label, Long-term Extension Study to Evaluate the Safety, Tolerability and Efficacy of 12 Months of LCZ696 Treatment in Patients With Essential Hypertension [EXTENSION OF 700059183]

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2016

At a glance

  • Drugs Sacubitril/valsartan (Primary)
  • Indications Essential hypertension
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 08 Apr 2013 New trial record
    • 27 Mar 2013 Status changed from active, no longer recruiting, to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top